# A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

> **NCT04945733** · PHASE2 · TERMINATED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 62 (actual)

## Conditions studied

- Stomach Neoplasms
- Esophageal Neoplasms

## Interventions

- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT04945733
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-30
- **Primary completion:** 2023-07-03
- **Final completion:** 2023-07-03
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Due to reconsideration of development strategy
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04945733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04945733, "A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04945733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*